Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Oct;13(5):327-34.
doi: 10.1007/s11934-012-0274-9.

Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care

David R Staskin  1 , Kenneth M Peters, Scott MacDiarmid, Neal Shore, William C de Groat
Affiliations
Review

Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care

David R Staskin et al. Curr Urol Rep. 2012 Oct.

Abstract

Overactive bladder affects millions of adults, with profound personal and economic costs. Although antimuscarinic drugs can cause a reduction in voiding symptoms, the effect is modest, and many patients are intolerant of the side effects, or do not experience sufficient relief. For these patients, the modulation of bladder reflex pathways via percutaneous tibial nerve stimulation (PTNS) or via implanted sacral nerve stimulation (SNS) has been acknowledged as a logical next step in the algorithm of care. This review examines the mechanism of action, the relative benefits, adverse effects, and costs of percutaneous nerve stimulation compared to other treatment modalities.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percutaneous tibial nerve stimulation in the outpatient setting. Reprinted with permission from Peters et al [••]
Fig. 2
Fig. 2
OAB treatment algorithm, progressing from the least expensive and noninvasive therapy of lifestyle and behavioral changes, through drug therapy, intermittent PTNS, surgically implanted SNS, and finally surgical interventions. (*Botulinum is not in the treatment algorithm as it is not currently an FDA approved therapy for idiopathic OAB.)
Fig. 3
Fig. 3
Relative costs of therapeutic options for overactive bladder
See this image and copyright information in PMC

References

    1. •• Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. 2012. The AUA/SUFU Guidelines for treatment and diagnosis of OAB present a thorough and definitive approach to the patient with OAB, including behavioral interventions, antimuscarinic drugs, and neuromodulation with PTNS and SNS.
    1. Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–6. doi: 10.1016/j.juro.2010.06.113. - DOI - PubMed
    1. Govier FE, Litwiller S, Nitti V, Kreder KJ, Jr, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165(4):1193–8. doi: 10.1016/S0022-5347(05)66469-5. - DOI - PubMed
    1. MacDiarmid SA, Peters KM, Shobeiri SA, Wooldridge LS, Rovner ES, Leong FC, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183(1):234–40. doi: 10.1016/j.juro.2009.08.160. - DOI - PubMed
    1. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–43. doi: 10.1016/j.juro.2009.12.036. - DOI - PubMed

Substances